Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies

Michael E Thase1 Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania and the Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA, [email protected]Correspondence[email protected]

Emmanuelle Weiller2 Medical Affairs, H. Lundbeck A/S, Valby, Copenhagen, Denmark

Peter Zhang3 Biostatistics Department, Otsuka Pharmaceutical Development and Commercialization Inc., Princeton, NJ, USA

Catherine Weiss4 Global Medical Affairs, Otsuka Pharmaceutical Development and Commercialization Inc., Princeton, NJ, USA

Roger S McIntyre5 Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada

Figures & data

Table 1 Overlap between anxious distress and anxious depression

Download CSV Display Table

Table 2 Patient disposition stratified by the presence or absence of anxious distress and anxious depression at baseline

Download CSV Display Table

Table 3 Baseline demographic and clinical characteristics stratified by the presence or absence of anxious distress and anxious depression at baseline

Download CSV Display Table

Figure 1 Effect of brexpiprazole and placebo as adjunct to ADT on MADRS Total score, stratified by the presence or absence of anxious distress (A, B) and anxious depression (C, D) at baseline.

Notes: *P<0.05, **P<0.01, ***P<0.001 vs placebo. Baseline MADRS Total scores (ADT + placebo, ADT + brexpiprazole): (A) 29.1, 28.9; (B) 23.5, 23.8; (C) 28.6, 28.9; (D) 24.8, 24.6. Post hoc analysis of data from three 6-week, randomized, double-blind, placebo-controlled studies in patients with major depressive disorder and inadequate response to ADTs (Pyxis, Polaris, and Sirius). Data were pooled for patients randomized to brexpiprazole 2 mg/day and 3 mg/day, and for patients randomized to placebo.
Abbreviations: ADT, antidepressant treatment; LS, least squares; MADRS, Montgomery–Åsberg Depression Rating Scale; SE, standard error.

Table 4 TEAEs stratified by the presence or absence of anxious distress and anxious depression at baseline

Download CSV Display Table

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies

Table 1 Overlap between anxious distress and anxious depression

Table 2 Patient disposition stratified by the presence or absence of anxious distress and anxious depression at baseline

Table 3 Baseline demographic and clinical characteristics stratified by the presence or absence of anxious distress and anxious depression at baseline

Table 4 TEAEs stratified by the presence or absence of anxious distress and anxious depression at baseline

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: post hoc analyses of three placebo-controlled studies

Figures & data

Table 1 Overlap between anxious distress and anxious depression

Table 2 Patient disposition stratified by the presence or absence of anxious distress and anxious depression at baseline

Table 3 Baseline demographic and clinical characteristics stratified by the presence or absence of anxious distress and anxious depression at baseline

Table 4 TEAEs stratified by the presence or absence of anxious distress and anxious depression at baseline

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date